Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.
Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
- Conditions
- Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: Lu-PSMA-617
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06738303
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇨🇦
Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada
🇩🇰Vejle Sygehus, Vejle, Denmark
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Conditions
- Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Other: Genetic testingProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Bone scanProcedure: FDG-Positron Emission TomographyProcedure: PSMA PET ScanProcedure: Biospecimen Collection
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT06632977
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸UC San Diego Health System - Encinitas, Encinitas, California, United States
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- Conditions
- Stage IVB Prostate Cancer AJCC v8Castration-Resistant Prostate Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 528
- Registration Number
- NCT06470243
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06353386
- Locations
- 🇹🇷
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1800), Ankara, Turkey
🇺🇸UCSD Moores Cancer Center ( Site 0039), La Jolla, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles, California, United States
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06085729
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT05818683
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
🇺🇸Perlmutter Cancer Center at NYU Langone Brooklyn, Brooklyn, New York, United States
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 42
- Registration Number
- NCT05563558
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate CancermCRPC
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 35
- Registration Number
- NCT05340374
- Locations
- 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.